IL111681A0 - Recombinant viruses and their use in gene therapy - Google Patents
Recombinant viruses and their use in gene therapyInfo
- Publication number
- IL111681A0 IL111681A0 IL11168194A IL11168194A IL111681A0 IL 111681 A0 IL111681 A0 IL 111681A0 IL 11168194 A IL11168194 A IL 11168194A IL 11168194 A IL11168194 A IL 11168194A IL 111681 A0 IL111681 A0 IL 111681A0
- Authority
- IL
- Israel
- Prior art keywords
- gene therapy
- recombinant viruses
- viruses
- recombinant
- therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9313772A FR2712603B1 (en) | 1993-11-18 | 1993-11-18 | Recombinant viruses, preparation and use in gene therapy. |
Publications (1)
Publication Number | Publication Date |
---|---|
IL111681A0 true IL111681A0 (en) | 1995-01-24 |
Family
ID=9452977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11168194A IL111681A0 (en) | 1993-11-18 | 1994-11-17 | Recombinant viruses and their use in gene therapy |
Country Status (5)
Country | Link |
---|---|
AU (1) | AU8147294A (en) |
FR (1) | FR2712603B1 (en) |
IL (1) | IL111681A0 (en) |
WO (1) | WO1995014102A1 (en) |
ZA (1) | ZA949104B (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992015680A1 (en) | 1991-03-06 | 1992-09-17 | Board Of Regents, The University Of Texas System | Methods and compositions for the selective inhibition of gene expression |
US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
DE69524740T2 (en) * | 1994-05-02 | 2002-08-14 | Univ Washington Seattle | Thymidine kinase MUTANT |
EP1369487A3 (en) | 1994-08-16 | 2004-04-07 | Crucell Holland B.V. | Recombinant vectors derived from adenovirus for use in gene therapy |
FR2725213B1 (en) * | 1994-10-04 | 1996-11-08 | Rhone Poulenc Rorer Sa | VIRAL VECTORS AND USE IN GENE THERAPY |
US6638762B1 (en) | 1994-11-28 | 2003-10-28 | Genetic Therapy, Inc. | Tissue-vectors specific replication and gene expression |
US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
US6054467A (en) * | 1996-07-05 | 2000-04-25 | Sidney Kimmel Cancer Center | Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis |
US5958892A (en) | 1996-07-30 | 1999-09-28 | Board Of Regents, The University Of Texas System | 2-methoxyestradiol-induced apoptosis in cancer cells |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
DE69838483T2 (en) | 1997-10-14 | 2008-07-03 | Darwin Molecular Corp. | THYMIDINKINASE MUTANES AND FUSION PROTEINS WITH THYMIDINE KINASE AND GUANYLATEKINASE ACTIVITIES |
EP2278006A3 (en) | 1997-11-06 | 2011-03-02 | Novartis Vaccines and Diagnostics S.r.l. | Neisserial antigens |
JP4399112B2 (en) | 1998-01-14 | 2010-01-13 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Neisseria Meningitidis antigen |
ATE344322T1 (en) | 1998-02-13 | 2006-11-15 | Koester Hubert | USE OF RIBOZYMES TO DETERMINE THE FUNCTION OF GENES |
EP2261351A3 (en) | 1998-05-01 | 2012-01-11 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
CN1074459C (en) * | 1998-11-25 | 2001-11-07 | 马丁 | Adenovirus-thymidine kinase gene configuration, and its acquiring process and application |
EP2290083B1 (en) | 1999-04-30 | 2014-08-20 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
BR0015137A (en) | 1999-10-29 | 2003-03-25 | Chiron Spa | Neisserial antigenic peptides |
DK2289545T3 (en) | 2000-01-17 | 2016-09-05 | Glaxosmithkline Biologicals Sa | Supplemented OMV vaccine against meningococcus |
GB0008966D0 (en) | 2000-04-13 | 2000-05-31 | Imp College Innovations Ltd | Vectors for gene therapy |
AU2002214127B2 (en) | 2000-10-27 | 2007-06-07 | J. Craig Venter Institute, Inc. | Nucleic acids and proteins from streptococcus groups A and B |
CN1405312A (en) * | 2001-01-18 | 2003-03-26 | 中山卫健生物科技有限公司 | Recombinant virus capable of specific killing tumor relating to EB virus and constructing method thereof |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
CA2469620A1 (en) | 2001-12-12 | 2003-06-19 | Chiron Srl. | Immunisation against chlamydia trachomatis |
EP1545575A4 (en) | 2002-09-19 | 2006-04-05 | Us Gov Health & Human Serv | P. ariasi polypeptides, p. perniciosus polypeptides and methods of use |
US7485306B2 (en) | 2002-10-29 | 2009-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Lutzomyia longipalpis polypeptides and methods of use |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
EP1736541B1 (en) | 2004-03-29 | 2013-01-23 | Galpharma Co., Ltd. | Novel modified galectin 9 protein and use thereof |
GB0413702D0 (en) | 2004-06-18 | 2004-07-21 | Molmed Spa | Thymidine kinase |
PT1881845E (en) | 2005-04-25 | 2010-05-31 | Merial Ltd | Nipah virus vaccines |
US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
EP3147296A1 (en) | 2005-11-14 | 2017-03-29 | Merial, Inc. | Gene therapy for renal failure |
US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
ATE522541T1 (en) | 2006-06-09 | 2011-09-15 | Novartis Ag | BACTERIAL ADHESIN CONFORMERS |
WO2009137577A2 (en) | 2008-05-08 | 2009-11-12 | Merial Limited | Leishmania vaccine using sand fly salivary immunogen |
AU2012245395A1 (en) | 2011-04-20 | 2013-11-14 | Merial, Inc. | Adjuvanted rabies vaccine with improved viscosity profile |
CA2837375C (en) | 2011-06-01 | 2019-07-16 | Merial Limited | Needle-free administration of prrsv vaccines |
IN2014CN00547A (en) | 2011-07-20 | 2015-04-03 | Merial Ltd | |
EP3215188A1 (en) | 2014-11-03 | 2017-09-13 | Merial, Inc. | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8919607D0 (en) * | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
CA2091346C (en) * | 1990-09-14 | 2007-04-24 | Philip Frost | Methods and compositions for genetic therapy and potentiation of anti-tumor immunity |
FR2688514A1 (en) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
-
1993
- 1993-11-18 FR FR9313772A patent/FR2712603B1/en not_active Expired - Fee Related
-
1994
- 1994-11-07 WO PCT/FR1994/001285 patent/WO1995014102A1/en active Application Filing
- 1994-11-07 AU AU81472/94A patent/AU8147294A/en not_active Abandoned
- 1994-11-16 ZA ZA949104A patent/ZA949104B/en unknown
- 1994-11-17 IL IL11168194A patent/IL111681A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
FR2712603B1 (en) | 1996-02-09 |
AU8147294A (en) | 1995-06-06 |
WO1995014102A1 (en) | 1995-05-26 |
ZA949104B (en) | 1995-07-21 |
FR2712603A1 (en) | 1995-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL111681A0 (en) | Recombinant viruses and their use in gene therapy | |
IL115584A0 (en) | Viral vectors and their use in gene therapy | |
ZA945012B (en) | Viral vectors and their use in gene therapy | |
ZA951803B (en) | Recombinant viruses their preparation and their therapeutic use | |
ZA952563B (en) | Recombinant viruses their preparation and their use in gene therapy | |
IL111682A0 (en) | Recombinant viruses and their use in gene therapy | |
AU4032893A (en) | Human papilloma virus genes and their use in gene therapy | |
SG54275A1 (en) | Dna coding for decarbamylase improved in thermostability and use thereof | |
GB9214857D0 (en) | Human nucleic acid fragments and their use | |
EP0623020A4 (en) | Pyropheophorbides and their use in photodynamic therapy. | |
GB9414925D0 (en) | Electrode and preparation thereof | |
IL105914A0 (en) | Methods and compositions for in vivo gene therapy | |
EP0752472A4 (en) | Novel gene originating in corynebacterium and use thereof | |
ZA956849B (en) | Use of a defective recombinant adenovirus in gene therapy | |
IL117466A0 (en) | Recombinant viruses expressing lecithin-cholesterol acryltransferase and their use in gene therapy | |
ZA952242B (en) | Recombinant viruses their preparation and their use in gene therapy | |
AU7665396A (en) | Recombinant viruses containing mobile genetic elements and methods of use in gene therapy | |
ZA952244B (en) | Recombinant viruses their preparation and their use in gene therapy | |
GB2279956B (en) | Recombinant human and rat AMP-protein kinases | |
ZA952286B (en) | Recombinant viruses their preparation and their use in gene therapy | |
EP0692537A3 (en) | Recombinant gibberellin DNA and uses thereof | |
ZA952243B (en) | Recombinant viruses their preparation and their use in gene therapy | |
EP0690917A4 (en) | Recombinant epstein-barr virus protein and its use in vaccine | |
GB9501907D0 (en) | Allatostatins and their use | |
GB9405875D0 (en) | Recombinant molecules and their use in gene transfer |